Skip to content Loading the Research Gap Index…
Unmet need · computed index
Research Gap Index How a cancer's share of deaths compares with its share of registered research activity — active interventional trials (ClinicalTrials.gov) and publications of the last five years (PubMed) — within one burden scope. It measures where registered activity is thin relative to mortality; it does not measure the quality, funding or difficulty of research, and it inherits every limit of the burden source.
Computed ci-research-gap-components-v1 ci-trial-gap-ratio-v1 ci-research-gap-ratio-v1 Methodology Trial Gap Ratio ranking Research Gap Ratio ranking
Burden is currently United States only (CDC WONDER and U.S. Cancer Statistics): global estimates (IARC / GLOBOCAN) remain under license review, so no world scope exists yet. Shares and ratios are relative to the eligible top-level cancers of the scope, not to all cancers.
USA · 2024 Scope both sexes · all ages · top-level cancers 35 Eligible cancers of 36 with a mortality observation · deaths ≥ 100 546,737 Σ deaths cdc-wonder · 2024 · eligible set 19,872 Σ active trials ClinicalTrials.gov · cancer + NCIt descendants 580,388 Σ publications (5 y) PubMed · query-based per entity Data updated 16 hours ago · Source updated unknown · components ci-research-gap-components-v1 · sums are over the eligible set only
Burden vs literature
Annual deaths vs publications of the last five years Each bubble is one eligible top-level cancer; bubble area is proportional to its active interventional trials. The dashed line is the scope's overall intensity (1,062 publications per 1,000 deaths): cancers below it have a positive Research Gap Ratio — fewer publications than their share of deaths would suggest — and cancers above it a negative one.
Scatter of annual deaths against publications for 35 eligible top-level cancers, USA 2024 100 1,000 10,000 100,000 300 1,000 3,000 10,000 30,000 100,000
Burden vs clinical research
Annual deaths vs active interventional trials Dashed line: 36.3 active trials per 1,000 deaths (Trial Gap Ratio = 0). Below the line: positive Trial Gap Ratio.
Scatter of annual deaths against active trials for 35 eligible top-level cancers, USA 2024 30 100 300 1,000 3,000 300 1,000 3,000 10,000 30,000 100,000
Components
Deaths, activity, shares and gap ratios per cancer Click a column header to sort (the order is kept in the URL). Ineligible cancers are listed last with the reason. Shares are the cancer's fraction of the eligible set's total; ratios are log₂(death share ÷ activity share): 0 = proportional, +1 = twice the death share, −1 = half.
cdc-wonder clinicaltrials pubmed Computed 36 top-level cancers with a 2024 mortality observation · 35 eligible 300,000 Annual deaths, 2024 (log scale) Publications, last 5 years (log scale) Scope average: 1,062 publications per 1,000 deaths (Research Gap Ratio = 0) Malignant Lung Neoplasm — deaths 128,762 (2024) · publications 5 y 93,034 · active trials 2,644 · research gap ratio +0.56 Lung Malignant Breast Neoplasm — deaths 43,897 (2024) · publications 5 y 133,010 · active trials 2,627 · research gap ratio -1.51 Breast Non-Hodgkin Lymphoma — deaths 19,882 (2024) · publications 5 y 17,190 · active trials 2,168 · research gap ratio +0.3 Non-Hodgkin Lymphoma Leukemia — deaths 23,740 (2024) · publications 5 y 31,893 · active trials 1,769 · research gap ratio -0.34 Leukemia Malignant Prostate Neoplasm — deaths 34,815 (2024) · publications 5 y 52,116 · active trials 1,375 · research gap ratio -0.5 Prostate Malignant Liver Neoplasm — deaths 30,532 (2024) · publications 5 y 17,939 · active trials 906 · research gap ratio +0.85 Liver Malignant Pancreatic Neoplasm — deaths 51,327 (2024) · publications 5 y 25,767 · active trials 904 · research gap ratio +1.08 Pancreatic Malignant Central Nervous System Neoplasm — deaths 18,523 (2024) · publications 5 y 298 · active trials 823 · research gap ratio +6.04 Central Nervous System Multiple Myeloma — deaths 11,967 (2024) · publications 5 y 10,244 · active trials 814 · research gap ratio +0.31 Multiple Myeloma Malignant Ovarian Neoplasm — deaths 12,654 (2024) · publications 5 y 25,793 · active trials 684 · research gap ratio -0.94 Ovarian Malignant Gastric Neoplasm — deaths 11,246 (2024) · publications 5 y 34,783 · active trials 652 · research gap ratio -1.54 Gastric Malignant Esophageal Neoplasm — deaths 16,274 (2024) · publications 5 y 10,921 · active trials 518 · research gap ratio +0.66 Esophageal Malignant Cervical Neoplasm — deaths 4,207 (2024) · publications 5 y 26,673 · active trials 505 · research gap ratio -2.58 Cervical Malignant Kidney Neoplasm — deaths 15,215 (2024) · publications 5 y 3,700 · active trials 453 · research gap ratio +2.13 Kidney Malignant Uterine Corpus Neoplasm — deaths 8,608 (2024) · publications 5 y 105 · active trials 411 · research gap ratio +6.44 Uterine Corpus Malignant Rectal Neoplasm — deaths 13,446 (2024) · publications 5 y 12,506 · active trials 386 · research gap ratio +0.19 Rectal Malignant Bladder Neoplasm — deaths 17,396 (2024) · publications 5 y 18,250 · active trials 346 · research gap ratio +0.02 Bladder Malignant Nasopharyngeal Neoplasm — deaths 664 (2024) · publications 5 y 952 · active trials 261 · research gap ratio -0.43 Nasopharyngeal Malignant Colon Neoplasm — deaths 40,801 (2024) · publications 5 y 18,406 · active trials 225 · research gap ratio +1.23 Colon Hodgkin Lymphoma — deaths 909 (2024) · publications 5 y 2,178 · active trials 179 · research gap ratio -1.17 Hodgkin Lymphoma Malignant Thyroid Gland Neoplasm — deaths 2,229 (2024) · publications 5 y 13,792 · active trials 176 · research gap ratio -2.54 Thyroid Gland Malignant Lip and Oral Cavity Neoplasm — deaths 5,424 (2024) · publications 5 y 8,195 · active trials 149 · research gap ratio -0.51 Lip and Oral Cavity Malignant Oropharyngeal Neoplasm — deaths 3,286 (2024) · publications 5 y 2,550 · active trials 143 · research gap ratio +0.45 Oropharyngeal Skin Carcinoma — deaths 5,462 (2024) · publications 5 y 2,868 · active trials 127 · research gap ratio +1.02 Skin Carcinoma Malignant Mesothelioma — deaths 2,114 (2024) · publications 5 y 2,145 · active trials 96 · research gap ratio +0.07 Mesothelioma Cutaneous Melanoma — deaths 8,671 (2024) · publications 5 y 4,407 · active trials 78 · research gap ratio +1.06 Cutaneous Melanoma Malignant Anal Neoplasm — deaths 1,651 (2024) · publications 5 y 1,291 · active trials 68 · research gap ratio +0.44 Anal Malignant Laryngeal Neoplasm — deaths 4,095 (2024) · publications 5 y 2,031 · active trials 66 · research gap ratio +1.1 Laryngeal Malignant Salivary Gland Neoplasm — deaths 1,173 (2024) · publications 5 y 474 · active trials 63 · research gap ratio +1.39 Salivary Gland Malignant Vulvar Neoplasm — deaths 1,555 (2024) · publications 5 y 870 · active trials 54 · research gap ratio +0.92 Vulvar Malignant Hypopharyngeal Neoplasm — deaths 498 (2024) · publications 5 y 581 · active trials 53 · research gap ratio -0.14 Hypopharyngeal Malignant Penile Neoplasm — deaths 415 (2024) · publications 5 y 1,025 · active trials 43 · research gap ratio -1.22 Penile Malignant Testicular Neoplasm — deaths 462 (2024) · publications 5 y 1,806 · active trials 43 · research gap ratio -1.88 Testicular Malignant Gallbladder Neoplasm — deaths 4,402 (2024) · publications 5 y 2,222 · active trials 32 · research gap ratio +1.07 Gallbladder Malignant Vaginal Neoplasm — deaths 435 (2024) · publications 5 y 373 · active trials 31 · research gap ratio +0.31 Vaginal Scope average: 1,062 publications per 1,000 deaths (Research Gap Ratio = 0)Active trials: 2,000 500 100
300,000 Annual deaths, 2024 (log scale) Active interventional trials (log scale) Scope average: 36.3 active trials per 1,000 deaths (Trial Gap Ratio = 0) Malignant Uterine Corpus Neoplasm — deaths 8,608 (2024) · active trials 411 · trial gap ratio -0.39 Uterine Corpus Malignant Central Nervous System Neoplasm — deaths 18,523 (2024) · active trials 823 · trial gap ratio -0.29 Central Nervous System Malignant Kidney Neoplasm — deaths 15,215 (2024) · active trials 453 · trial gap ratio +0.29 Kidney Malignant Salivary Gland Neoplasm — deaths 1,173 (2024) · active trials 63 · trial gap ratio -0.56 Salivary Gland Malignant Colon Neoplasm — deaths 40,801 (2024) · active trials 225 · trial gap ratio +2.72 Colon Malignant Laryngeal Neoplasm — deaths 4,095 (2024) · active trials 66 · trial gap ratio +1.17 Laryngeal Malignant Pancreatic Neoplasm — deaths 51,327 (2024) · active trials 904 · trial gap ratio +1.05 Pancreatic Malignant Gallbladder Neoplasm — deaths 4,402 (2024) · active trials 32 · trial gap ratio +2.32 Gallbladder Cutaneous Melanoma — deaths 8,671 (2024) · active trials 78 · trial gap ratio +2.01 Cutaneous Melanoma Skin Carcinoma — deaths 5,462 (2024) · active trials 127 · trial gap ratio +0.64 Skin Carcinoma Malignant Vulvar Neoplasm — deaths 1,555 (2024) · active trials 54 · trial gap ratio +0.07 Vulvar Malignant Liver Neoplasm — deaths 30,532 (2024) · active trials 906 · trial gap ratio +0.29 Liver Malignant Esophageal Neoplasm — deaths 16,274 (2024) · active trials 518 · trial gap ratio +0.19 Esophageal Malignant Lung Neoplasm — deaths 128,762 (2024) · active trials 2,644 · trial gap ratio +0.82 Lung Malignant Oropharyngeal Neoplasm — deaths 3,286 (2024) · active trials 143 · trial gap ratio -0.26 Oropharyngeal Malignant Anal Neoplasm — deaths 1,651 (2024) · active trials 68 · trial gap ratio -0.18 Anal Multiple Myeloma — deaths 11,967 (2024) · active trials 814 · trial gap ratio -0.9 Multiple Myeloma Malignant Vaginal Neoplasm — deaths 435 (2024) · active trials 31 · trial gap ratio -0.97 Vaginal Non-Hodgkin Lymphoma — deaths 19,882 (2024) · active trials 2,168 · trial gap ratio -1.59 Non-Hodgkin Lymphoma Malignant Rectal Neoplasm — deaths 13,446 (2024) · active trials 386 · trial gap ratio +0.34 Rectal Malignant Mesothelioma — deaths 2,114 (2024) · active trials 96 · trial gap ratio -0.32 Mesothelioma Malignant Bladder Neoplasm — deaths 17,396 (2024) · active trials 346 · trial gap ratio +0.87 Bladder Malignant Hypopharyngeal Neoplasm — deaths 498 (2024) · active trials 53 · trial gap ratio -1.55 Hypopharyngeal Leukemia — deaths 23,740 (2024) · active trials 1,769 · trial gap ratio -1.04 Leukemia Malignant Nasopharyngeal Neoplasm — deaths 664 (2024) · active trials 261 · trial gap ratio -3.43 Nasopharyngeal Malignant Prostate Neoplasm — deaths 34,815 (2024) · active trials 1,375 · trial gap ratio -0.12 Prostate Malignant Lip and Oral Cavity Neoplasm — deaths 5,424 (2024) · active trials 149 · trial gap ratio +0.4 Lip and Oral Cavity Malignant Ovarian Neoplasm — deaths 12,654 (2024) · active trials 684 · trial gap ratio -0.57 Ovarian Hodgkin Lymphoma — deaths 909 (2024) · active trials 179 · trial gap ratio -2.44 Hodgkin Lymphoma Malignant Penile Neoplasm — deaths 415 (2024) · active trials 43 · trial gap ratio -1.51 Penile Malignant Breast Neoplasm — deaths 43,897 (2024) · active trials 2,627 · trial gap ratio -0.72 Breast Malignant Gastric Neoplasm — deaths 11,246 (2024) · active trials 652 · trial gap ratio -0.67 Gastric Malignant Testicular Neoplasm — deaths 462 (2024) · active trials 43 · trial gap ratio -1.36 Testicular Malignant Thyroid Gland Neoplasm — deaths 2,229 (2024) · active trials 176 · trial gap ratio -1.12 Thyroid Gland Malignant Cervical Neoplasm — deaths 4,207 (2024) · active trials 505 · trial gap ratio -1.72 Cervical Scope average: 36.3 active trials per 1,000 deaths (Trial Gap Ratio = 0)
Malignant Uterine Corpus Neoplasm #20 / #1 8,608 2024 cdc-wonder 1.6% 411 2.1% 105 0% -0.39 +6.44 47.7 12.2 eligible inputs sums
deaths 546737
eligible 35
activeTrials 19872
publications5y 580388 thresholds
minDeaths 100
minActivity 1 activitySources
activeTrials CI-SOURCE-00000004
publications5y CI-SOURCE-00000005 ratioEligibility
trialGapRatio true
researchGapRatio true
literatureCountId 493
countersComputedAt 2026-09-29 02:00:20.557824-04
publicationsSource entity_counters.publication_count_5y
mortalityEstimateType observed
incidenceObservationId null
mortalityObservationId 10324
mortalitySiteDefinition C54
mortalityOtherObservationIds [] component 192633 · ci-research-gap-components-v1
Malignant Central Nervous System Neoplasm #18 / #2 18,523 2024 cdc-wonder 3.4% 823 4.1% 298 0.1% -0.29 +6.04 44.4 16.1 eligible inputs sums
deaths 546737
eligible 35
activeTrials 19872
publications5y 580388 thresholds
minDeaths 100
minActivity 1 activitySources
activeTrials CI-SOURCE-00000004 Malignant Kidney Neoplasm #12 / #3 15,215 2024 cdc-wonder 2.8% 453 2.3% 3,700 0.6% +0.29 +2.13 29.8 243.2 eligible inputs sums
deaths 546737
eligible 35
activeTrials 19872
publications5y 580388 thresholds
minDeaths 100
minActivity 1 activitySources
activeTrials CI-SOURCE-00000004
Malignant Salivary Gland Neoplasm #21 / #4 1,173 2024 cdc-wonder 0.2% 63 0.3% 474 0.1% -0.56 +1.39 53.7 404.1 eligible inputs sums
deaths 546737
eligible 35
activeTrials 19872
publications5y 580388 thresholds
minDeaths 100
minActivity 1 activitySources
activeTrials CI-SOURCE-00000004 Malignant Colon Neoplasm #1 / #5 40,801 2024 cdc-wonder 7.5% 225 1.1% 18,406 3.2% +2.72 +1.23 5.5 451.1 eligible inputs sums
deaths 546737
eligible 35
activeTrials 19872
publications5y 580388 thresholds
minDeaths 100
minActivity 1 activitySources
activeTrials CI-SOURCE-00000004 Malignant Laryngeal Neoplasm #4 / #6 4,095 2024 cdc-wonder 0.7% 66 0.3% 2,031 0.3% +1.17 +1.1 16.1 496 eligible inputs sums
deaths 546737
eligible 35
activeTrials 19872
publications5y 580388 thresholds
minDeaths 100
minActivity 1 activitySources
activeTrials CI-SOURCE-00000004 Malignant Pancreatic Neoplasm #5 / #7 51,327 2024 cdc-wonder 9.4% 904 4.5% 25,767 4.4% +1.05 +1.08 17.6 502 eligible inputs sums
deaths 546737
eligible 35
activeTrials 19872
publications5y 580388 thresholds
minDeaths 100
minActivity 1 activitySources
activeTrials CI-SOURCE-00000004 Malignant Gallbladder Neoplasm #2 / #8 4,402 2024 cdc-wonder 0.8% 32 0.2% 2,222 0.4% +2.32 +1.07 7.3 504.8 eligible inputs sums
deaths 546737
eligible 35
activeTrials 19872
publications5y 580388 thresholds
minDeaths 100
minActivity 1 activitySources
activeTrials CI-SOURCE-00000004 Cutaneous Melanoma #3 / #9 8,671 2024 cdc-wonder 1.6% 78 0.4% 4,407 0.8% +2.01 +1.06 9 508.2 eligible inputs sums
deaths 546737
eligible 35
activeTrials 19872
publications5y 580388 thresholds
minDeaths 100
minActivity 1 activitySources
activeTrials CI-SOURCE-00000004
Skin Carcinoma #8 / #10 5,462 2024 cdc-wonder 1% 127 0.6% 2,868 0.5% +0.64 +1.02 23.3 525.1 eligible inputs sums
deaths 546737
eligible 35
activeTrials 19872
publications5y 580388 thresholds
minDeaths 100
minActivity 1 activitySources
activeTrials CI-SOURCE-00000004
Malignant Vulvar Neoplasm #14 / #11 1,555 2024 cdc-wonder 0.3% 54 0.3% 870 0.1% +0.07 +0.92 34.7 559.5 eligible inputs sums
deaths 546737
eligible 35
activeTrials 19872
publications5y 580388 thresholds
minDeaths 100
minActivity 1 activitySources
activeTrials CI-SOURCE-00000004
Malignant Liver Neoplasm #11 / #12 30,532 2024 cdc-wonder 5.6% 906 4.6% 17,939 3.1% +0.29 +0.85 29.7 587.5 eligible inputs sums
deaths 546737
eligible 35
activeTrials 19872
publications5y 580388 thresholds
minDeaths 100
minActivity 1 activitySources
activeTrials CI-SOURCE-00000004
Malignant Esophageal Neoplasm #13 / #13 16,274 2024 cdc-wonder 3% 518 2.6% 10,921 1.9% +0.19 +0.66 31.8 671.1 eligible inputs sums
deaths 546737
eligible 35
activeTrials 19872
publications5y 580388 thresholds
minDeaths 100
minActivity 1 activitySources
activeTrials CI-SOURCE-00000004
Malignant Lung Neoplasm #7 / #14 128,762 2024 cdc-wonder 23.6% 2,644 13.3% 93,034 16% +0.82 +0.56 20.5 722.5 eligible inputs sums
deaths 546737
eligible 35
activeTrials 19872
publications5y 580388 thresholds
minDeaths 100
minActivity 1 activitySources
activeTrials CI-SOURCE-00000004
Malignant Oropharyngeal Neoplasm #17 / #15 3,286 2024 cdc-wonder 0.6% 143 0.7% 2,550 0.4% -0.26 +0.45 43.5 776 eligible inputs sums
deaths 546737
eligible 35
activeTrials 19872
publications5y 580388 thresholds
minDeaths 100
minActivity 1 activitySources
activeTrials CI-SOURCE-00000004
Malignant Anal Neoplasm #16 / #16 1,651 2024 cdc-wonder 0.3% 68 0.3% 1,291 0.2% -0.18 +0.44 41.2 782 eligible inputs sums
deaths 546737
eligible 35
activeTrials 19872
publications5y 580388 thresholds
minDeaths 100
minActivity 1 activitySources
activeTrials CI-SOURCE-00000004
Multiple Myeloma #25 / #17 11,967 2024 cdc-wonder 2.2% 814 4.1% 10,244 1.8% -0.9 +0.31 68 856 eligible inputs sums
deaths 546737
eligible 35
activeTrials 19872
publications5y 580388 thresholds
minDeaths 100
minActivity 1 activitySources
activeTrials CI-SOURCE-00000004
Malignant Vaginal Neoplasm #26 / #18 435 2024 cdc-wonder 0.1% 31 0.2% 373 0.1% -0.97 +0.31 71.3 857.5 eligible inputs sums
deaths 546737
eligible 35
activeTrials 19872
publications5y 580388 thresholds
minDeaths 100
minActivity 1 activitySources
activeTrials CI-SOURCE-00000004
Non-Hodgkin Lymphoma #32 / #19 19,882 2024 cdc-wonder 3.6% 2,168 10.9% 17,190 3% -1.59 +0.3 109 864.6 eligible inputs sums
deaths 546737
eligible 35
activeTrials 19872
publications5y 580388 thresholds
minDeaths 100
minActivity 1 activitySources
activeTrials CI-SOURCE-00000004
Malignant Rectal Neoplasm #10 / #20 13,446 2024 cdc-wonder 2.5% 386 1.9% 12,506 2.2% +0.34 +0.19 28.7 930.1 eligible inputs sums
deaths 546737
eligible 35
activeTrials 19872
publications5y 580388 thresholds
minDeaths 100
minActivity 1 activitySources
activeTrials CI-SOURCE-00000004
Malignant Mesothelioma #19 / #21 2,114 2024 cdc-wonder 0.4% 96 0.5% 2,145 0.4% -0.32 +0.07 45.4 1,014.7 eligible inputs sums
deaths 546737
eligible 35
activeTrials 19872
publications5y 580388 thresholds
minDeaths 100
minActivity 1 activitySources
activeTrials CI-SOURCE-00000004
Malignant Bladder Neoplasm #6 / #22 17,396 2024 cdc-wonder 3.2% 346 1.7% 18,250 3.1% +0.87 +0.02 19.9 1,049.1 eligible inputs sums
deaths 546737
eligible 35
activeTrials 19872
publications5y 580388 thresholds
minDeaths 100
minActivity 1 activitySources
activeTrials CI-SOURCE-00000004
Malignant Hypopharyngeal Neoplasm #31 / #23 498 2024 cdc-wonder 0.1% 53 0.3% 581 0.1% -1.55 -0.14 106.4 1,166.7 eligible inputs sums
deaths 546737
eligible 35
activeTrials 19872
publications5y 580388 thresholds
minDeaths 100
minActivity 1 activitySources
activeTrials CI-SOURCE-00000004
Leukemia #27 / #24 23,740 2024 cdc-wonder 4.3% 1,769 8.9% 31,893 5.5% -1.04 -0.34 74.5 1,343.4 eligible inputs sums
deaths 546737
eligible 35
activeTrials 19872
publications5y 580388 thresholds
minDeaths 100
minActivity 1 activitySources
activeTrials CI-SOURCE-00000004
publications5y Malignant Nasopharyngeal Neoplasm #35 / #25 664 2024 cdc-wonder 0.1% 261 1.3% 952 0.2% -3.43 -0.43 393.1 1,433.7 eligible inputs sums
deaths 546737
eligible 35
activeTrials 19872
publications5y 580388 thresholds
minDeaths 100
minActivity 1 activitySources
activeTrials CI-SOURCE-00000004
Malignant Prostate Neoplasm #15 / #26 34,815 2024 cdc-wonder 6.4% 1,375 6.9% 52,116 9% -0.12 -0.5 39.5 1,496.9 eligible inputs sums
deaths 546737
eligible 35
activeTrials 19872
publications5y 580388 thresholds
minDeaths 100
minActivity 1 activitySources
activeTrials CI-SOURCE-00000004
Malignant Lip and Oral Cavity Neoplasm #9 / #27 5,424 2024 cdc-wonder 1% 149 0.7% 8,195 1.4% +0.4 -0.51 27.5 1,510.9 eligible inputs sums
deaths 546737
eligible 35
activeTrials 19872
publications5y 580388 thresholds
minDeaths 100
minActivity 1 activitySources
activeTrials CI-SOURCE-00000004
Malignant Ovarian Neoplasm #22 / #28 12,654 2024 cdc-wonder 2.3% 684 3.4% 25,793 4.4% -0.57 -0.94 54.1 2,038.3 eligible inputs sums
deaths 546737
eligible 35
activeTrials 19872
publications5y 580388 thresholds
minDeaths 100
minActivity 1 activitySources
activeTrials CI-SOURCE-00000004
Hodgkin Lymphoma #34 / #29 909 2024 cdc-wonder 0.2% 179 0.9% 2,178 0.4% -2.44 -1.17 196.9 2,396 eligible inputs sums
deaths 546737
eligible 35
activeTrials 19872
publications5y 580388 thresholds
minDeaths 100
minActivity 1 activitySources
activeTrials CI-SOURCE-00000004
Malignant Penile Neoplasm #30 / #30 415 2024 cdc-wonder 0.1% 43 0.2% 1,025 0.2% -1.51 -1.22 103.6 2,469.9 eligible inputs sums
deaths 546737
eligible 35
activeTrials 19872
publications5y 580388 thresholds
minDeaths 100
minActivity 1 activitySources
activeTrials CI-SOURCE-00000004
Malignant Breast Neoplasm #24 / #31 43,897 2024 cdc-wonder 8% 2,627 13.2% 133,010 22.9% -0.72 -1.51 59.8 3,030 eligible inputs sums
deaths 546737
eligible 35
activeTrials 19872
publications5y 580388 thresholds
minDeaths 100
minActivity 1 activitySources
activeTrials CI-SOURCE-00000004
Malignant Gastric Neoplasm #23 / #32 11,246 2024 cdc-wonder 2.1% 652 3.3% 34,783 6% -0.67 -1.54 58 3,092.9 eligible inputs sums
deaths 546737
eligible 35
activeTrials 19872
publications5y 580388 thresholds
minDeaths 100
minActivity 1 activitySources
activeTrials CI-SOURCE-00000004
Malignant Testicular Neoplasm #29 / #33 462 2024 cdc-wonder 0.1% 43 0.2% 1,806 0.3% -1.36 -1.88 93.1 3,909.1 eligible inputs sums
deaths 546737
eligible 35
activeTrials 19872
publications5y 580388 thresholds
minDeaths 100
minActivity 1 activitySources
activeTrials CI-SOURCE-00000004
Malignant Thyroid Gland Neoplasm #28 / #34 2,229 2024 cdc-wonder 0.4% 176 0.9% 13,792 2.4% -1.12 -2.54 79 6,187.5 eligible inputs sums
deaths 546737
eligible 35
activeTrials 19872
publications5y 580388 thresholds
minDeaths 100
minActivity 1 activitySources
activeTrials CI-SOURCE-00000004
Malignant Cervical Neoplasm #33 / #35 4,207 2024 cdc-wonder 0.8% 505 2.5% 26,673 4.6% -1.72 -2.58 120 6,340.1 eligible inputs sums
deaths 546737
eligible 35
activeTrials 19872
publications5y 580388 thresholds
minDeaths 100
minActivity 1 activitySources
activeTrials CI-SOURCE-00000004
Kaposi Sarcoma 56 2024 cdc-wonder — 18 — 871 — — — 321.4 15,553.6 deaths below threshold inputs sums
deaths 546737
eligible 35
activeTrials 19872
publications5y 580388 thresholds
minDeaths 100
minActivity 1 activitySources
activeTrials CI-SOURCE-00000004
publications5y CI-SOURCE-00000005
Data updated 16 hours ago · Source updated unknown · computed Sep 29, 2026, 06:16 AM UTC · ci-research-gap-components-v1
Read with care
What this index is not Not a judgement of research quality, funding or difficulty — only registered activity counted against deaths. A positive ratio is a signal to look closer, not an accusation. Trial counts aggregate a cancer and its NCIt descendants; registrations phrased at a broader level (e.g. “colorectal cancer”) are attributed to the broader entity and can overstate the gap of narrower sites. Literature counts are query-based per entity (the query is stored with each count) and are not aggregated over descendants; a narrow query can inflate a Research Gap Ratio. Burden depends on the epidemiology source and its site definitions; the same cancer can have a different ratio under another source or year. Compare only within one table. United States only for now; a US death share is not a global death share. Shares are relative to the eligible set: adding or removing one cancer changes every other cancer’s ratio slightly.
publications5y CI-SOURCE-00000005 ratioEligibility
trialGapRatio true
researchGapRatio true
countersComputedAt 2026-09-29 02:00:20.557824-04
publicationsSource entity_counters.publication_count_5y
mortalityEstimateType observed
incidenceObservationId null
mortalityObservationId 10765
mortalitySiteDefinition C70-C72
mortalityOtherObservationIds [] component 192603 · ci-research-gap-components-v1
publications5y
CI-SOURCE-00000005 ratioEligibility
trialGapRatio true
researchGapRatio true
countersComputedAt 2026-09-29 02:00:20.557824-04
publicationsSource entity_counters.publication_count_5y
mortalityEstimateType observed
incidenceObservationId null
mortalityObservationId 10639
mortalitySiteDefinition C64-C65
mortalityOtherObservationIds [] component 192614 · ci-research-gap-components-v1
publications5y CI-SOURCE-00000005 ratioEligibility
trialGapRatio true
researchGapRatio true
countersComputedAt 2026-09-29 02:00:20.557824-04
publicationsSource entity_counters.publication_count_5y
mortalityEstimateType observed
incidenceObservationId null
mortalityObservationId 8944
mortalitySiteDefinition C07-C08
mortalityOtherObservationIds [] component 192609 · ci-research-gap-components-v1
publications5y CI-SOURCE-00000005 ratioEligibility
trialGapRatio true
researchGapRatio true
countersComputedAt 2026-09-29 02:00:20.557824-04
publicationsSource entity_counters.publication_count_5y
mortalityEstimateType observed
incidenceObservationId null
mortalityObservationId 9322
mortalitySiteDefinition C18
mortalityOtherObservationIds [] component 192631 · ci-research-gap-components-v1
publications5y CI-SOURCE-00000005 ratioEligibility
trialGapRatio true
researchGapRatio true
countersComputedAt 2026-09-29 02:00:20.557824-04
publicationsSource entity_counters.publication_count_5y
mortalityEstimateType observed
incidenceObservationId null
mortalityObservationId 9700
mortalitySiteDefinition C32
mortalityOtherObservationIds [] component 192615 · ci-research-gap-components-v1
publications5y CI-SOURCE-00000005 ratioEligibility
trialGapRatio true
researchGapRatio true
countersComputedAt 2026-09-29 02:00:20.557824-04
publicationsSource entity_counters.publication_count_5y
mortalityEstimateType observed
incidenceObservationId null
mortalityObservationId 9637
mortalitySiteDefinition C25
mortalityOtherObservationIds [] component 192608 · ci-research-gap-components-v1
publications5y CI-SOURCE-00000005 ratioEligibility
trialGapRatio true
researchGapRatio true
countersComputedAt 2026-09-29 02:00:20.557824-04
publicationsSource entity_counters.publication_count_5y
mortalityEstimateType observed
incidenceObservationId null
mortalityObservationId 9574
mortalitySiteDefinition C23-C24
mortalityOtherObservationIds [] component 192613 · ci-research-gap-components-v1
publications5y
CI-SOURCE-00000005 ratioEligibility
trialGapRatio true
researchGapRatio true
countersComputedAt 2026-09-29 02:00:20.557824-04
publicationsSource entity_counters.publication_count_5y
mortalityEstimateType observed
incidenceObservationId null
mortalityObservationId 9826
mortalitySiteDefinition C43
mortalityOtherObservationIds [] component 192601 · ci-research-gap-components-v1
publications5y
CI-SOURCE-00000005 ratioEligibility
trialGapRatio true
researchGapRatio true
countersComputedAt 2026-09-29 02:00:20.557824-04
publicationsSource entity_counters.publication_count_5y
mortalityEstimateType observed
incidenceObservationId null
mortalityObservationId 9889
mortalitySiteDefinition C44
mortalityOtherObservationIds [] component 192612 · ci-research-gap-components-v1
publications5y
CI-SOURCE-00000005 ratioEligibility
trialGapRatio true
researchGapRatio true
countersComputedAt 2026-09-29 02:00:20.557824-04
publicationsSource entity_counters.publication_count_5y
mortalityEstimateType observed
incidenceObservationId null
mortalityObservationId 10135
mortalitySiteDefinition C51
mortalityOtherObservationIds [] component 192628 · ci-research-gap-components-v1
publications5y
CI-SOURCE-00000005 ratioEligibility
trialGapRatio true
researchGapRatio true
countersComputedAt 2026-09-29 02:00:20.557824-04
publicationsSource entity_counters.publication_count_5y
mortalityEstimateType observed
incidenceObservationId null
mortalityObservationId 9511
mortalitySiteDefinition C22
mortalityOtherObservationIds [] component 192616 · ci-research-gap-components-v1
publications5y
CI-SOURCE-00000005 ratioEligibility
trialGapRatio true
researchGapRatio true
countersComputedAt 2026-09-29 02:00:20.557824-04
publicationsSource entity_counters.publication_count_5y
mortalityEstimateType observed
incidenceObservationId null
mortalityObservationId 9196
mortalitySiteDefinition C15
mortalityOtherObservationIds [] component 192604 · ci-research-gap-components-v1
publications5y
CI-SOURCE-00000005 ratioEligibility
trialGapRatio true
researchGapRatio true
countersComputedAt 2026-09-29 02:00:20.557824-04
publicationsSource entity_counters.publication_count_5y
mortalityEstimateType observed
incidenceObservationId null
mortalityObservationId 9763
mortalitySiteDefinition C33-C34
mortalityOtherObservationIds [] component 192607 · ci-research-gap-components-v1
publications5y
CI-SOURCE-00000005 ratioEligibility
trialGapRatio true
researchGapRatio true
countersComputedAt 2026-09-29 02:00:20.557824-04
publicationsSource entity_counters.publication_count_5y
mortalityEstimateType observed
incidenceObservationId null
mortalityObservationId 9007
mortalitySiteDefinition C09-C10
mortalityOtherObservationIds [] component 192623 · ci-research-gap-components-v1
publications5y
CI-SOURCE-00000005 ratioEligibility
trialGapRatio true
researchGapRatio true
countersComputedAt 2026-09-29 02:00:20.557824-04
publicationsSource entity_counters.publication_count_5y
mortalityEstimateType observed
incidenceObservationId null
mortalityObservationId 9448
mortalitySiteDefinition C21
mortalityOtherObservationIds [] component 192629 · ci-research-gap-components-v1
publications5y
CI-SOURCE-00000005 ratioEligibility
trialGapRatio true
researchGapRatio true
countersComputedAt 2026-09-29 02:00:20.557824-04
publicationsSource entity_counters.publication_count_5y
mortalityEstimateType observed
incidenceObservationId null
mortalityObservationId 11017
mortalitySiteDefinition C88, C90
mortalityOtherObservationIds [] component 192610 · ci-research-gap-components-v1
publications5y
CI-SOURCE-00000005 ratioEligibility
trialGapRatio true
researchGapRatio true
countersComputedAt 2026-09-29 02:00:20.557824-04
publicationsSource entity_counters.publication_count_5y
mortalityEstimateType observed
incidenceObservationId null
mortalityObservationId 10198
mortalitySiteDefinition C52
mortalityOtherObservationIds [] component 192627 · ci-research-gap-components-v1
publications5y
CI-SOURCE-00000005 ratioEligibility
trialGapRatio true
researchGapRatio true
countersComputedAt 2026-09-29 02:00:20.557824-04
publicationsSource entity_counters.publication_count_5y
mortalityEstimateType observed
incidenceObservationId null
mortalityObservationId 10954
mortalitySiteDefinition C82-C85, C96
mortalityOtherObservationIds [] component 192611 · ci-research-gap-components-v1
publications5y
CI-SOURCE-00000005 ratioEligibility
trialGapRatio true
researchGapRatio true
countersComputedAt 2026-09-29 02:00:20.557824-04
publicationsSource entity_counters.publication_count_5y
mortalityEstimateType observed
incidenceObservationId null
mortalityObservationId 9385
mortalitySiteDefinition C19-C20
mortalityOtherObservationIds [] component 192632 · ci-research-gap-components-v1
publications5y
CI-SOURCE-00000005 ratioEligibility
trialGapRatio true
researchGapRatio true
countersComputedAt 2026-09-29 02:00:20.557824-04
publicationsSource entity_counters.publication_count_5y
mortalityEstimateType observed
incidenceObservationId null
mortalityObservationId 9952
mortalitySiteDefinition C45
mortalityOtherObservationIds [] component 192600 · ci-research-gap-components-v1
publications5y
CI-SOURCE-00000005 ratioEligibility
trialGapRatio true
researchGapRatio true
countersComputedAt 2026-09-29 02:00:20.557824-04
publicationsSource entity_counters.publication_count_5y
mortalityEstimateType observed
incidenceObservationId null
mortalityObservationId 10702
mortalitySiteDefinition C67
mortalityOtherObservationIds [] component 192620 · ci-research-gap-components-v1
publications5y
CI-SOURCE-00000005 ratioEligibility
trialGapRatio true
researchGapRatio true
countersComputedAt 2026-09-29 02:00:20.557824-04
publicationsSource entity_counters.publication_count_5y
mortalityEstimateType observed
incidenceObservationId null
mortalityObservationId 9133
mortalitySiteDefinition C12-C13
mortalityOtherObservationIds [] component 192621 · ci-research-gap-components-v1
CI-SOURCE-00000005 ratioEligibility
trialGapRatio true
researchGapRatio true
countersComputedAt 2026-09-29 02:00:20.557824-04
publicationsSource entity_counters.publication_count_5y
mortalityEstimateType observed
incidenceObservationId null
mortalityObservationId 11080
mortalitySiteDefinition C91-C95
mortalityOtherObservationIds [] component 192598 · ci-research-gap-components-v1
publications5y
CI-SOURCE-00000005 ratioEligibility
trialGapRatio true
researchGapRatio true
countersComputedAt 2026-09-29 02:00:20.557824-04
publicationsSource entity_counters.publication_count_5y
mortalityEstimateType observed
incidenceObservationId null
mortalityObservationId 9070
mortalitySiteDefinition C11
mortalityOtherObservationIds [] component 192622 · ci-research-gap-components-v1
publications5y
CI-SOURCE-00000005 ratioEligibility
trialGapRatio true
researchGapRatio true
countersComputedAt 2026-09-29 02:00:20.557824-04
publicationsSource entity_counters.publication_count_5y
mortalityEstimateType observed
incidenceObservationId null
mortalityObservationId 10513
mortalitySiteDefinition C61
mortalityOtherObservationIds [] component 192625 · ci-research-gap-components-v1
publications5y
CI-SOURCE-00000005 ratioEligibility
trialGapRatio true
researchGapRatio true
countersComputedAt 2026-09-29 02:00:20.557824-04
publicationsSource entity_counters.publication_count_5y
mortalityEstimateType observed
incidenceObservationId null
mortalityObservationId 8881
mortalitySiteDefinition C00-C06
mortalityOtherObservationIds [] component 192606 · ci-research-gap-components-v1
publications5y
CI-SOURCE-00000005 ratioEligibility
trialGapRatio true
researchGapRatio true
countersComputedAt 2026-09-29 02:00:20.557824-04
publicationsSource entity_counters.publication_count_5y
mortalityEstimateType observed
incidenceObservationId null
mortalityObservationId 10387
mortalitySiteDefinition C56
mortalityOtherObservationIds [] component 192617 · ci-research-gap-components-v1
publications5y
CI-SOURCE-00000005 ratioEligibility
trialGapRatio true
researchGapRatio true
countersComputedAt 2026-09-29 02:00:20.557824-04
publicationsSource entity_counters.publication_count_5y
mortalityEstimateType observed
incidenceObservationId null
mortalityObservationId 10891
mortalitySiteDefinition C81
mortalityOtherObservationIds [] component 192602 · ci-research-gap-components-v1
publications5y
CI-SOURCE-00000005 ratioEligibility
trialGapRatio true
researchGapRatio true
countersComputedAt 2026-09-29 02:00:20.557824-04
publicationsSource entity_counters.publication_count_5y
mortalityEstimateType observed
incidenceObservationId null
mortalityObservationId 10450
mortalitySiteDefinition C60
mortalityOtherObservationIds [] component 192624 · ci-research-gap-components-v1
publications5y
CI-SOURCE-00000005 ratioEligibility
trialGapRatio true
researchGapRatio true
countersComputedAt 2026-09-29 02:00:20.557824-04
publicationsSource entity_counters.publication_count_5y
mortalityEstimateType observed
incidenceObservationId null
mortalityObservationId 10072
mortalitySiteDefinition C50
mortalityOtherObservationIds [] component 192599 · ci-research-gap-components-v1
publications5y
CI-SOURCE-00000005 ratioEligibility
trialGapRatio true
researchGapRatio true
countersComputedAt 2026-09-29 02:00:20.557824-04
publicationsSource entity_counters.publication_count_5y
mortalityEstimateType observed
incidenceObservationId null
mortalityObservationId 9259
mortalitySiteDefinition C16
mortalityOtherObservationIds [] component 192605 · ci-research-gap-components-v1
publications5y
CI-SOURCE-00000005 ratioEligibility
trialGapRatio true
researchGapRatio true
countersComputedAt 2026-09-29 02:00:20.557824-04
publicationsSource entity_counters.publication_count_5y
mortalityEstimateType observed
incidenceObservationId null
mortalityObservationId 10576
mortalitySiteDefinition C62
mortalityOtherObservationIds [] component 192626 · ci-research-gap-components-v1
publications5y
CI-SOURCE-00000005 ratioEligibility
trialGapRatio true
researchGapRatio true
countersComputedAt 2026-09-29 02:00:20.557824-04
publicationsSource entity_counters.publication_count_5y
mortalityEstimateType observed
incidenceObservationId null
mortalityObservationId 10828
mortalitySiteDefinition C73
mortalityOtherObservationIds [] component 192618 · ci-research-gap-components-v1
publications5y
CI-SOURCE-00000005 ratioEligibility
trialGapRatio true
researchGapRatio true
countersComputedAt 2026-09-29 02:00:20.557824-04
publicationsSource entity_counters.publication_count_5y
mortalityEstimateType observed
incidenceObservationId null
mortalityObservationId 10261
mortalitySiteDefinition C53
mortalityOtherObservationIds [] component 192630 · ci-research-gap-components-v1
ratioEligibility
trialGapRatio false
researchGapRatio false
countersComputedAt 2026-09-29 02:00:20.557824-04
publicationsSource entity_counters.publication_count_5y
mortalityEstimateType observed
incidenceObservationId null
mortalityObservationId 10009
mortalitySiteDefinition C46
mortalityOtherObservationIds [] component 192619 · ci-research-gap-components-v1